196 related articles for article (PubMed ID: 37269109)
1. Chemotherapy and Immune Checkpoint Inhibitors in a Case of SMARCA4-dUT: A Case Report and Review of Literature.
Pokhrel A; Yadav R; Manvar KK; Wu R; Jaswani V; Wasserman CB; Wang JC
J Investig Med High Impact Case Rep; 2023; 11():23247096231176220. PubMed ID: 37269109
[TBL] [Abstract][Full Text] [Related]
2. SMARCA4-Deficient Undifferentiated Tumor of Lung Mass-A Rare Tumor With the Rarer Occurrence of Brain Metastasis: A Case Report and Review of the Literature.
Yadav R; Sun L; Salyana M; Eric M; Gotlieb V; Wang JC
J Investig Med High Impact Case Rep; 2022; 10():23247096221074864. PubMed ID: 35356840
[TBL] [Abstract][Full Text] [Related]
3. [Thoracic
Xiong Y; Zhang B; Nie LG; Wu SK; Zhao H; Li D; DI JT
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):351-356. PubMed ID: 37042149
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment with tislelizumab plus chemotherapy for SMARCA4-deficient undifferentiated tumor: a case report.
Dong W; Dai A; Wu Z; Wang J; Wu T; Du Y; Tian W; Zheng J; Zhang Y; Wang H; Cai J; Dong S; Zhou Y; Li S; Xiao Z
Front Immunol; 2024; 15():1371379. PubMed ID: 38881888
[TBL] [Abstract][Full Text] [Related]
5. Promising efficacy of immune checkpoint inhibitor plus chemotherapy for thoracic SMARCA4-deficient undifferentiated tumor.
Lin Y; Yu B; Sun H; Zhang H; Hu Z; Zhang Y; Wu Z; Sun S; Zhao X; Yu H; Wu X; Li Y; Wang J; Wang H
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8663-8671. PubMed ID: 37115272
[TBL] [Abstract][Full Text] [Related]
6. Thoracic SMARCA4-deficient undifferentiated tumor-a case of an aggressive neoplasm-case report.
Roden AC
Mediastinum; 2021; 5():39. PubMed ID: 35118344
[TBL] [Abstract][Full Text] [Related]
7. [Evaluation of Efficacy and Prognosis Analysis of Stage III-IV SMARCA4-deficient
Non-small Cell Lung Cancer Treated by PD-1 Immune Checkpoint Inhibitors plus
Chemotherapy and Chemotherapy].
Wang X; Tu M; Jia H; Liu H; Wang Y; Wang Y; Jiang N; Lu C; Zhang G
Zhongguo Fei Ai Za Zhi; 2023 Sep; 26(9):659-668. PubMed ID: 37985152
[TBL] [Abstract][Full Text] [Related]
8. SMARCA4-deficient thoracic sarcoma: a distinctive clinicopathological entity with undifferentiated rhabdoid morphology and aggressive behavior.
Sauter JL; Graham RP; Larsen BT; Jenkins SM; Roden AC; Boland JM
Mod Pathol; 2017 Oct; 30(10):1422-1432. PubMed ID: 28643792
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Deficient Thoracic Tumor.
Shinno Y; Yoshida A; Masuda K; Matsumoto Y; Okuma Y; Yoshida T; Goto Y; Horinouchi H; Yamamoto N; Yatabe Y; Ohe Y
Clin Lung Cancer; 2022 Jul; 23(5):386-392. PubMed ID: 35618627
[TBL] [Abstract][Full Text] [Related]
10. Molecular, clinicopathological characteristics and surgical results of resectable SMARCA4-deficient thoracic tumors.
Luo J; Ding B; Campisi A; Chen T; Teng H; Ji C
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4455-4463. PubMed ID: 36121510
[TBL] [Abstract][Full Text] [Related]
11. Recent updates in thoracic SMARCA4-deficient undifferentiated tumor.
Nambirajan A; Jain D
Semin Diagn Pathol; 2021 Sep; 38(5):83-89. PubMed ID: 34147303
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment with nivolumab for SMARCA4-deficient non-small cell lung carcinoma with a high tumor mutation burden: A case report.
Naito T; Umemura S; Nakamura H; Zenke Y; Udagawa H; Kirita K; Matsumoto S; Yoh K; Niho S; Motoi N; Aokage K; Tsuboi M; Ishii G; Goto K
Thorac Cancer; 2019 May; 10(5):1285-1288. PubMed ID: 30972962
[TBL] [Abstract][Full Text] [Related]
13. Rare SMARCA4-deficient thoracic tumor: Insights into molecular characterization and optimal therapeutics methods.
Shi M; Pang L; Zhou H; Mo S; Sheng J; Zhang Y; Liu J; Sun D; Gong L; Wang J; Zhuang W; Huang Y; Chen Z; Zhao Y; Li J; Huang Y; Yang Y; Fang W; Zhang L
Lung Cancer; 2024 Jun; 192():107818. PubMed ID: 38763102
[TBL] [Abstract][Full Text] [Related]
14. Immune-Desert Tumor Microenvironment in Thoracic SMARCA4-Deficient Undifferentiated Tumors with Limited Efficacy of Immune Checkpoint Inhibitors.
Gantzer J; Davidson G; Vokshi B; Weingertner N; Bougoüin A; Moreira M; Lindner V; Lacroix G; Mascaux C; Chenard MP; Bertucci F; Davidson I; Kurtz JE; Sautès-Fridman C; Fridman WH; Malouf GG
Oncologist; 2022 Jun; 27(6):501-511. PubMed ID: 35278076
[TBL] [Abstract][Full Text] [Related]
15. Cytology of SMARCA4-Deficient Thoracic Neoplasms: Comparative Analysis of SMARCA4-Deficient Non-Small Cell Lung Carcinomas and SMARCA4-Deficient Thoracic Sarcomas.
Nambirajan A; Dutta R; Malik PS; Bubendorf L; Jain D
Acta Cytol; 2021; 65(1):67-74. PubMed ID: 32854100
[TBL] [Abstract][Full Text] [Related]
16. Expanding the Immunophenotype Spectrum of SMARCA4-Deficient Non-Small Cell Lung Carcinomas: A Case Series with Neuroendocrine Markers Expression.
Mao R; Liu M; Shu X; Li W; Yan W; Li X
Int J Surg Pathol; 2022 May; 30(3):251-259. PubMed ID: 34633874
[No Abstract] [Full Text] [Related]
17. Update on genetically defined lung neoplasms: NUT carcinoma and thoracic SMARCA4-deficient undifferentiated tumors.
Chatzopoulos K; Boland JM
Virchows Arch; 2021 Jan; 478(1):21-30. PubMed ID: 33409598
[TBL] [Abstract][Full Text] [Related]
18. SWI/SNF Complex-deficient Undifferentiated/Rhabdoid Carcinomas of the Gastrointestinal Tract: A Series of 13 Cases Highlighting Mutually Exclusive Loss of SMARCA4 and SMARCA2 and Frequent Co-inactivation of SMARCB1 and SMARCA2.
Agaimy A; Daum O; Märkl B; Lichtmannegger I; Michal M; Hartmann A
Am J Surg Pathol; 2016 Apr; 40(4):544-53. PubMed ID: 26551623
[TBL] [Abstract][Full Text] [Related]
19. SMARCA4-deficient Thoracic Sarcomas: Clinicopathologic Study of 30 Cases With an Emphasis on Their Nosology and Differential Diagnoses.
Perret R; Chalabreysse L; Watson S; Serre I; Garcia S; Forest F; Yvorel V; Pissaloux D; Thomas de Montpreville V; Masliah-Planchon J; Lantuejoul S; Brevet M; Blay JY; Coindre JM; Tirode F; Le Loarer F
Am J Surg Pathol; 2019 Apr; 43(4):455-465. PubMed ID: 30451731
[TBL] [Abstract][Full Text] [Related]
20. SMARCA4-Deficient Undifferentiated Tumor: A Rare Malignancy With Distinct Clinicopathological Characteristics.
Al-Shbool G; Krishnan Nair H
Cureus; 2022 Oct; 14(10):e30708. PubMed ID: 36439610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
